Viridian Therapeutics Inc (VRDN) stock saw a modest uptick, ending the day at $18.13 which represents a slight increase of $1.07 or 6.27% from the prior close of $17.06. The stock opened at $17.31 and ...

Analyst Rami Katkhuda from LifeSci Capital maintained a Buy rating on Viridian Therapeutics (VRDN – Research Report) and keeping the price ...

About Viridian Therapeutics Viridian is a biopharmaceutical company focused on engineering and developing potential best-in-class medicines for patients with serious and rare diseases.

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announces the ...

January 08, 2025--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare ...

January 08, 2025--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare ...

Across the recent three months, 10 analysts have shared their insights on Viridian Therapeutics (NASDAQ:VRDN), expressing a variety of opinions spanning from bullish to bearish. In the table below ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Viridian Therapeutics, Inc. has a fifty-two week low of $11.40 and a fifty-two week high of $27.20. The firm has a market cap of $1.53 billion, a P/E ratio of -4.48 and a beta of 1.04. The company ...

Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN – Get Free Report) were down 3.4% during trading on Tuesday . The stock traded as low as $18.77 and last traded at $19.01. Approximately 81,134 ...